anurajms/meta_analysis huggingface dataset:
MESH terms:
Interventions for the management of malignant pleural effusions: a network meta‐analysis
1. *Network Meta‐Analysis; 2. Bleomycin [therapeutic use]; 3. Doxycycline [therapeutic use]; 4. Dyspnea [therapy]; 5. Fever [etiology]; 6. Iodine [therapeutic use]; 7. Pleural Effusion, Malignant [etiology, mortality, *therapy]; 8. Pleurodesis [*methods, mortality]; 9. Quinacrine [therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Talc [therapeutic use]; 12. Treatment Failure;
MESH terms:
Health education interventions to promote early presentation and referral for women with symptoms of endometrial cancer
1. *Endometrial Neoplasms [diagnosis]; 2. *Health Education [methods]; 3. *Health Knowledge, Attitudes, Practice; 4. *Referral and Consultation; 5. Awareness; 6. Randomized Controlled Trials as Topic; 7. Uterine Hemorrhage [diagnosis, etiology];
MESH terms:
Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer
1. Antineoplastic Agents, Hormonal [*therapeutic use]; 2. Breast Neoplasms [mortality, *therapy]; 3. Chemotherapy, Adjuvant; 4. Gonadotropin‐Releasing Hormone [*agonists]; 5. Premenopause; 6. Randomized Controlled Trials as Topic; 7. Survival Analysis; 8. Tamoxifen [therapeutic use]; 9. Treatment Outcome;
MESH terms:
Drugs for preventing lung cancer in healthy people
1. *Dietary Supplements; 2. *Health Status; 3. Ascorbic Acid [therapeutic use]; 4. Calcium, Dietary [adverse effects, therapeutic use]; 5. Cholecalciferol [therapeutic use]; 6. Confidence Intervals; 7. Incidence; 8. Lung Neoplasms [epidemiology, mortality, *prevention & control]; 9. Minerals [*therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Selenium; 12. Selenium Compounds [therapeutic use]; 13. Sex Factors; 14. Vitamin A [adverse effects, therapeutic use]; 15. Vitamin E [therapeutic use]; 16. Vitamins [adverse effects, *therapeutic use]; 17. alpha‐Tocopherol [adverse effects, therapeutic use]; 18. beta Carotene [therapeutic use];
MESH terms:
Exercise therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
1. *Exercise Therapy [methods]; 2. Aromatase Inhibitors [*adverse effects, therapeutic use]; 3. Breast Neoplasms [drug therapy]; 4. Musculoskeletal Pain [*chemically induced, *prevention & control]; 5. Neoplasm Staging; 6. Randomized Controlled Trials as Topic;
MESH terms:
Hormone replacement therapy after surgery for epithelial ovarian cancer
1. *Hormone Replacement Therapy; 2. Carcinoma, Ovarian Epithelial [*drug therapy, surgery]; 3. Menopause, Premature [drug effects]; 4. Ovarian Neoplasms [*drug therapy, surgery]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Drug therapy for delirium in terminally ill adults
1. Antipsychotic Agents [*therapeutic use]; 2. Chlorpromazine [therapeutic use]; 3. Delirium [*drug therapy, etiology]; 4. Haloperidol [therapeutic use]; 5. Lorazepam [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Terminally Ill [*psychology];
MESH terms:
Different infusion durations for preventing platinum‐induced hearing loss in children with cancer
1. Antineoplastic Agents [administration & dosage, *adverse effects]; 2. Carboplatin [administration & dosage, adverse effects]; 3. Cisplatin [administration & dosage, adverse effects]; 4. Disease‐Free Survival; 5. Hearing Loss [*chemically induced]; 6. Organoplatinum Compounds [administration & dosage, *adverse effects]; 7. Oxaliplatin [administration & dosage, adverse effects]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Tinnitus [chemically induced];
MESH terms:
Early versus delayed postoperative radiotherapy for treatment of low‐grade gliomas
1. Brain Neoplasms [mortality, *radiotherapy, surgery]; 2. Disease‐Free Survival; 3. Glioma [*radiotherapy, surgery]; 4. Postoperative Care; 5. Progression‐Free Survival; 6. Radiosurgery; 7. Radiotherapy [methods]; 8. Randomized Controlled Trials as Topic; 9. Time Factors; 10. Watchful Waiting;
MESH terms:
Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer
1. Antineoplastic Agents [therapeutic use]; 2. Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; 3. Carboplatin [therapeutic use]; 4. Carcinoma, Non‐Small‐Cell Lung [*drug therapy]; 5. Cisplatin [therapeutic use]; 6. Lung Neoplasms [*drug therapy]; 7. Nausea [chemically induced]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Survival Rate; 11. Treatment Outcome; 12. Vomiting [chemically induced];
MESH terms:
Intravesical Bacillus Calmette‐Guérin versus mitomycin C for Ta and T1 bladder cancer
1. Administration, Intravesical; 2. Antibiotics, Antineoplastic [administration & dosage, *therapeutic use]; 3. BCG Vaccine; 4. Carcinoma, Transitional Cell [*drug therapy]; 5. Mitomycin [administration & dosage, *therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Treatment Outcome; 8. Urinary Bladder Neoplasms [*drug therapy];
MESH terms:
Interval brain imaging for adults with cerebral glioma
1. Brain Neoplasms [*diagnostic imaging, mortality, surgery]; 2. Controlled Before‐After Studies; 3. Glioma [*diagnostic imaging, mortality, surgery]; 4. Magnetic Resonance Imaging [*methods]; 5. Randomized Controlled Trials as Topic; 6. Reoperation;
MESH terms:
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males
1. Dose‐Response Relationship, Immunologic; 2. Papillomavirus Infections [*prevention & control]; 3. Papillomavirus Vaccines [*administration & dosage]; 4. Randomized Controlled Trials as Topic; 5. Uterine Cervical Neoplasms [prevention & control, virology];
MESH terms:
Follow‐up strategies following completion of primary cancer treatment in adult cancer survivors
1. *Cancer Survivors [psychology]; 2. *Patient Satisfaction; 3. Anxiety [rehabilitation]; 4. Continuity of Patient Care; 5. Depression [rehabilitation]; 6. Fatigue [rehabilitation]; 7. Follow‐Up Studies; 8. Neoplasm Recurrence, Local [*diagnosis]; 9. Quality of Life; 10. Randomized Controlled Trials as Topic;
MESH terms:
Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery
1. *Antibiotic Prophylaxis; 2. Breast Neoplasms [*surgery]; 3. Mastectomy; 4. Preoperative Care [methods]; 5. Randomized Controlled Trials as Topic; 6. Surgical Wound Infection [*prevention & control]; 7. Wound Healing;
MESH terms:
Follow‐up strategies for patients treated for non‐metastatic colorectal cancer
1. Colorectal Neoplasms [*drug therapy, *surgery]; 2. Disease‐Free Survival; 3. Follow‐Up Studies; 4. Neoplasm Recurrence, Local; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Taxanes for adjuvant treatment of early breast cancer
1. *Antineoplastic Combined Chemotherapy Protocols; 2. Antineoplastic Agents, Phytogenic [*therapeutic use]; 3. Breast Neoplasms [*drug therapy]; 4. Chemotherapy, Adjuvant; 5. Neoadjuvant Therapy; 6. Paclitaxel [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Taxoids [*therapeutic use];
MESH terms:
Hypofractionation for clinically localized prostate cancer
1. Prostatic Neoplasms [*radiotherapy]; 2. Quality of Life; 3. *Radiation Dose Hypofractionation; 4. Randomized Controlled Trials as Topic; 5. Treatment Outcome;
MESH terms:
Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery
1. Abdomen [surgery]; 2. Anticoagulants [*therapeutic use]; 3. Drug Administration Schedule; 4. Heparin, Low‐Molecular‐Weight [*therapeutic use]; 5. Pelvis [surgery]; 6. Postoperative Complications [epidemiology, prevention & control]; 7. Postoperative Hemorrhage [epidemiology, *prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Venous Thromboembolism [epidemiology, *prevention & control];
MESH terms:
Long‐term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma
1. Antineoplastic Agents [*adverse effects, therapeutic use]; 2. Cognition Disorders [*chemically induced, epidemiology]; 3. Glioma [*therapy]; 4. Radiation Injuries [*complications]; 5. Radiosurgery; 6. Radiotherapy [*adverse effects, methods]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of hospital stay and postoperative complications
1. *Digestive System Surgical Procedures; 2. *Length of Stay; 3. Enteral Nutrition [*methods]; 4. Postoperative Complications [*prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Time Factors;
MESH terms:
Psychosocial interventions for informal caregivers of people living with cancer
1. *Anxiety [therapy]; 2. *Caregivers [psychology]; 3. *Depression [therapy]; 4. Health Status; 5. *Neoplasms [nursing]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic;
MESH terms:
Exercise training undertaken by people within 12 months of lung resection for non‐small cell lung cancer
1. *Exercise Therapy; 2. Breathing Exercises; 3. Carcinoma, Non‐Small‐Cell Lung [*rehabilitation, surgery]; 4. Exercise Tolerance [*physiology]; 5. Forced Expiratory Volume [physiology]; 6. Health Status; 7. Lung Neoplasms [*rehabilitation, surgery]; 8. Muscle Strength [physiology]; 9. Oxygen Consumption; 10. Postoperative Care [methods]; 11. Quadriceps Muscle [physiology]; 12. Quality of Life; 13. Randomized Controlled Trials as Topic; 14. Resistance Training; 15. Time Factors;
MESH terms:
Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer
1. Disease Progression; 2. *Prostate-Specific Antigen [therapeutic use]; 3. *Prostatic Neoplasms [drug therapy]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic;
MESH terms:
Perioperative nutrition for the treatment of bladder cancer by radical cystectomy
1. Cystectomy [*methods]; 2. Length of Stay; 3. Nutritional Status; 4. *Perioperative Care; 5. Postoperative Complications [*epidemiology]; 6. Urinary Bladder Neoplasms [*surgery]; 7. Wound Healing;
MESH terms:
Single‐dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma
1. *Administration, Intravesical; 2. Antineoplastic Agents [*administration & dosage, therapeutic use]; 3. Carcinoma [*drug therapy]; 4. Nephroureterectomy; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome; 7. Ureteral Neoplasms [*drug therapy];
MESH terms:
Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy
1. *Cystectomy [methods]; 2. *Lymph Node Excision; 3. Carcinoma, Transitional Cell [*surgery]; 4. Postoperative Complications; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome; 7. Urinary Bladder Neoplasms [*surgery];
MESH terms:
Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer
1. Antineoplastic Agents [*adverse effects, therapeutic use]; 2. Carboplatin; 3. Cisplatin; 4. Hearing Loss [*chemically induced, *prevention & control]; 5. Neoplasms [drug therapy]; 6. Organoplatinum Compounds [*adverse effects, therapeutic use]; 7. Oxaliplatin; 8. Randomized Controlled Trials as Topic;
MESH terms:
Risk‐reducing medications for primary breast cancer: a network meta‐analysis
1. Aromatase Inhibitors [*therapeutic use]; 2. Breast Neoplasms [*drug therapy]; 3. Network Meta‐Analysis; 4. Randomized Controlled Trials as Topic; 5. Selective Estrogen Receptor Modulators [*therapeutic use];
MESH terms:
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
1. *Hematopoietic Stem Cell Transplantation; 2. Antibodies, Monoclonal [*therapeutic use]; 3. Consolidation Chemotherapy; 4. Disease‐Free Survival; 5. Immunologic Factors [therapeutic use]; 6. Immunotherapy; 7. Neuroblastoma [immunology, mortality, *therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Robotic versus open radical cystectomy for bladder cancer in adults
1. Cystectomy [*methods]; 2. Postoperative Complications [epidemiology]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. Robotic Surgical Procedures [*methods]; 6. Treatment Outcome; 7. Urinary Bladder Neoplasms [*surgery];
MESH terms:
Mindfulness‐based stress reduction for women diagnosed with breast cancer
1. *Mindfulness; 2. Anxiety [psychology]; 3. Breast Neoplasms [*psychology]; 4. Depression [psychology]; 5. Fatigue [psychology]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Sleep Wake Disorders [psychology]; 9. Stress, Psychological [*therapy]; 10. Time Factors;
MESH terms:
Systematic screening and assessment of psychosocial well‐being and care needs of people with cancer
1. *Mental Health; 2. *Needs Assessment; 3. *Quality of Life; 4. Neoplasms [diagnosis, *psychology]; 5. Non‐Randomized Controlled Trials as Topic; 6. Randomized Controlled Trials as Topic; 7. Stress, Psychological [diagnosis];
MESH terms:
Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event
1. *Ambulatory Care; 2. Anti-Bacterial Agents [*therapeutic use]; 3. Febrile Neutropenia [chemically induced, *drug therapy, mortality]; 4. Fever [etiology]; 5. *Hospitalization; 6. Length of Stay; 7. Neoplasms [*complications]; 8. Outcome Assessment, Health Care; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Time Factors; 12. Treatment Failure;
MESH terms:
Palliative interventions for controlling vaginal bleeding in advanced cervical cancer
1. Antifibrinolytic Agents [therapeutic use]; 2. Palliative Care [*methods]; 3. Tampons, Surgical; 4. Tranexamic Acid [therapeutic use]; 5. Uterine Cervical Neoplasms [*complications, pathology]; 6. Uterine Hemorrhage [etiology, *therapy];
MESH terms:
Psychological interventions for parents of children and adolescents with chronic illness
1. Chronic Disease [*psychology]; 2. Cognitive Behavioral Therapy; 3. Family Relations; 4. Family Therapy; 5. Motivational Interviewing; 6. Parenting [psychology]; 7. Parents [*psychology]; 8. Problem Solving; 9. Psychotherapy [*methods]; 10. Randomized Controlled Trials as Topic;
MESH terms:
Intralesional treatment versus wide resection for central low‐grade chondrosarcoma of the long bones
1. Bone Neoplasms [mortality, pathology, *surgery]; 2. Chondrosarcoma [mortality, pathology, *surgery]; 3. Curettage [adverse effects, *methods]; 4. Disease‐Free Survival; 5. Kaplan‐Meier Estimate; 6. Neoplasm Grading; 7. Neoplasm Recurrence, Local; 8. Retrospective Studies;
MESH terms:
Non‐invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients
1. *Continuous Positive Airway Pressure [mortality, statistics & numerical data]; 2. *Noninvasive Ventilation [mortality, statistics & numerical data]; 3. Anti‐Bacterial Agents [therapeutic use]; 4. Intensive Care Units [statistics & numerical data]; 5. Length of Stay; 6. Lung Neoplasms [*surgery]; 7. Pneumonectomy [*adverse effects]; 8. Postoperative Complications [epidemiology, *prevention & control]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure in premenopausal women
1. Administration, Intranasal; 2. Antineoplastic Agents [adverse effects]; 3. Gonadotropin-Releasing Hormone [agonists, *analogs & derivatives]; 4. Injections, Intramuscular; 5. Injections, Subcutaneous; 6. Menstruation [*drug effects]; 7. Ovulation [drug effects]; 8. Pregnancy Rate; 9. *Premenopause; 10. Primary Ovarian Insufficiency [chemically induced, *prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Recovery of Function [drug effects];
MESH terms:
Systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults
1. Administration, Oral; 2. Adrenal Cortex Hormones [administration & dosage, adverse effects, *therapeutic use]; 3. Dexamethasone [administration & dosage, adverse effects, *therapeutic use]; 4. Dyspnea [*drug therapy, etiology]; 5. Neoplasms [*complications];
MESH terms:
Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment
1. Anastomosis, Surgical [methods]; 2. Arm; 3. Breast Neoplasms [*radiotherapy, *surgery]; 4. Lymphatic Vessels [radiation effects, *surgery, transplantation]; 5. Lymphedema [etiology, *prevention & control, *surgery]; 6. Postoperative Complications [*prevention & control, *surgery]; 7. Randomized Controlled Trials as Topic; 8. Reproducibility of Results; 9. Venules [*surgery];
MESH terms:
Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults
1. *Radiotherapy, Conformal [adverse effects]; 2. Carcinoma, Hepatocellular [metabolism, mortality, *therapy]; 3. Cause of Death; 4. Chemoembolization, Therapeutic [adverse effects, *methods]; 5. Combined Modality Therapy [adverse effects, methods]; 6. Liver Neoplasms [metabolism, mortality, *therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa)
1. *Autonomic Nervous System; 2. Disease‐Free Survival; 3. Hysterectomy [adverse effects, *methods]; 4. Neoplasm Recurrence, Local; 5. Neoplasm Staging; 6. Organ Sparing Treatments [adverse effects, *methods, mortality]; 7. Pelvis [innervation]; 8. Postoperative Complications [*prevention & control]; 9. Randomized Controlled Trials as Topic; 10. Urinary Bladder [*innervation]; 11. Urination Disorders [etiology, *prevention & control]; 12. Uterine Cervical Neoplasms [pathology, *surgery];
MESH terms:
De‐intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV‐positive oropharyngeal carcinoma
1. *Papillomaviridae; 2. Carcinoma, Squamous Cell [surgery, *therapy, *virology]; 3. Chemoradiotherapy, Adjuvant [*methods, standards]; 4. Laser Therapy [methods]; 5. Microsurgery [methods]; 6. Oropharyngeal Neoplasms [surgery, *therapy, *virology]; 7. Radiotherapy Dosage; 8. Robotic Surgical Procedures;
MESH terms:
Exercise interventions for people undergoing multimodal cancer treatment that includes surgery
1. *Exercise; 2. *Physical Fitness; 3. Breast Neoplasms [surgery, therapy]; 4. Combined Modality Therapy; 5. Fatigue [prevention & control]; 6. Home Care Services; 7. Muscle Strength; 8. Neoplasms [surgery, *therapy]; 9. Patient Safety; 10. Quality of Life; 11. Randomized Controlled Trials as Topic;
MESH terms:
Anti‐angiogenic therapy for high‐grade glioma
1. Angiogenesis Inhibitors [adverse effects, *therapeutic use]; 2. Antibodies, Monoclonal, Humanized [adverse effects, therapeutic use]; 3. Antineoplastic Agents [therapeutic use]; 4. Bevacizumab [therapeutic use]; 5. Brain Neoplasms [blood supply, *drug therapy, mortality]; 6. Camptothecin [analogs & derivatives, therapeutic use]; 7. Dacarbazine [analogs & derivatives, therapeutic use]; 8. Glioblastoma [blood supply, *drug therapy, mortality]; 9. Hypertension [chemically induced]; 10. Irinotecan [therapeutic use]; 11. Lomustine [therapeutic use]; 12. Neoplasm Recurrence, Local [drug therapy]; 13. Neovascularization, Pathologic [*drug therapy, mortality]; 14. Progression-Free Survival; 15. Proteinuria [chemically induced]; 16. Randomized Controlled Trials as Topic; 17. Snake Venoms [therapeutic use]; 18. Temozolomide [therapeutic use];
MESH terms:
Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer
1. *Time‐to‐Treatment; 2. Antineoplastic Agents [adverse effects, *therapeutic use]; 3. Asymptomatic Diseases [*therapy]; 4. Colonic Neoplasms [*drug therapy, *mortality, pathology]; 5. Confidence Intervals; 6. Diarrhea [chemically induced]; 7. Drug Administration Schedule; 8. Nausea [chemically induced]; 9. Palliative Care [*statistics & numerical data]; 10. Proportional Hazards Models; 11. Randomized Controlled Trials as Topic; 12. Rectal Neoplasms [*drug therapy, *mortality, pathology]; 13. Stomatitis [chemically induced]; 14. Survival Analysis; 15. Vomiting [chemically induced];
MESH terms:
Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer
1. Antineoplastic Agents [adverse effects]; 2. Leukopenia [etiology, *therapy]; 3. *Moxibustion; 4. Nausea [etiology, *therapy]; 5. Neoplasms [blood, *drug therapy, *radiotherapy]; 6. Platelet Count; 7. Publication Bias; 8. Quality of Life; 9. Radiotherapy [adverse effects]; 10. Randomized Controlled Trials as Topic; 11. Vomiting [etiology, *therapy];
MESH terms:
Laparoscopy versus laparotomy for the management of early stage endometrial cancer
1. Blood Loss, Surgical [statistics & numerical data]; 2. Disease‐Free Survival; 3. Endometrial Neoplasms [mortality, pathology, *surgery]; 4. Hysterectomy [adverse effects, *methods, mortality]; 5. Laparoscopy [adverse effects, *methods, mortality]; 6. Laparotomy [adverse effects, *methods, mortality]; 7. Length of Stay; 8. Neoplasm Recurrence, Local; 9. Postoperative Complications; 10. Randomized Controlled Trials as Topic;
MESH terms:
Extended‐field radiotherapy for locally advanced cervical cancer
1. Chemoradiotherapy; 2. Disease Progression; 3. Lymph Nodes [pathology]; 4. Lymphatic Irradiation [adverse effects, *methods]; 5. Lymphatic Metastasis [pathology, *radiotherapy]; 6. Neoplasm Recurrence, Local [pathology, radiotherapy]; 7. Pelvis; 8. Progression‐Free Survival; 9. Randomized Controlled Trials as Topic; 10. Uterine Cervical Neoplasms [drug therapy, mortality, pathology, *radiotherapy];
MESH terms:
Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer
1. Androgen Antagonists [*therapeutic use]; 2. Antineoplastic Agents, Hormonal [adverse effects, *therapeutic use]; 3. Disease Progression; 4. Prostatic Neoplasms [*drug therapy, mortality, pathology]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Taxoids [adverse effects, *therapeutic use]; 8. Withholding Treatment [statistics & numerical data];
MESH terms:
Epidermal growth factor receptor blockers for the treatment of ovarian cancer
1. Antibodies, Monoclonal [adverse effects, *therapeutic use]; 2. Antibodies, Monoclonal, Humanized [adverse effects, therapeutic use]; 3. Antineoplastic Agents [adverse effects, *therapeutic use]; 4. Deoxycytidine [*analogs & derivatives, therapeutic use]; 5. ErbB Receptors [*antagonists & inhibitors]; 6. Erlotinib Hydrochloride [adverse effects, therapeutic use]; 7. Neoplasm Recurrence, Local [drug therapy]; 8. Ovarian Neoplasms [*drug therapy, mortality]; 9. Piperidines [adverse effects, therapeutic use]; 10. Progression‐Free Survival; 11. Quality of Life; 12. Quinazolines [adverse effects, therapeutic use]; 13. Randomized Controlled Trials as Topic;
MESH terms:
Exercise for reducing falls in people living with and beyond cancer
1. Accidental Falls [*prevention & control]; 2. *Cancer Survivors; 3. *Exercise; 4. *Muscle Strength; 5. Neoplasms [*complications]; 6. Postural Balance; 7. Randomized Controlled Trials as Topic; 8. Range of Motion, Articular;
MESH terms:
Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer
1. *Chemoradiotherapy; 2. Hysterectomy [*methods]; 3. Neoplasm Staging; 4. Non‐Randomized Controlled Trials as Topic; 5. Uterine Cervical Neoplasms [pathology, *therapy];
MESH terms:
Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma
1. Anal Canal; 2. Dose Fractionation, Radiation; 3. Neoplasm Recurrence, Local [prevention & control]; 4. Organ Sparing Treatments; 5. Postoperative Complications [etiology]; 6. Preoperative Care; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Rectal Neoplasms [mortality, pathology, *radiotherapy, *surgery]; 10. Rectum [surgery];
MESH terms:
Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults
1. Antiemetics [adverse effects, *therapeutic use]; 2. Antineoplastic Agents [adverse effects]; 3. Benzodiazepines [adverse effects, *therapeutic use]; 4. Chemoradiotherapy [adverse effects]; 5. Dexamethasone [therapeutic use]; 6. Disorders of Excessive Somnolence [chemically induced]; 7. Fatigue; 8. Metoclopramide [therapeutic use]; 9. Nausea [*drug therapy, etiology, prevention & control]; 10. Neoplasms [*complications]; 11. Olanzapine; 12. Quality of Life; 13. Randomized Controlled Trials as Topic; 14. Vomiting [*drug therapy, etiology, prevention & control];
MESH terms:
Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with cancer
1. Diarrhea [complications, prevention & control, *therapy]; 2. Neoplasms [*drug therapy, *radiotherapy]; 3. Placebos [therapeutic use]; 4. Probiotics [*therapeutic use]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Immunonutrition for patients undergoing surgery for head and neck cancer
1. *Food, Fortified [adverse effects]; 2. Arginine [administration & dosage]; 3. Cause of Death; 4. Fatty Acids [administration & dosage]; 5. Fistula [epidemiology]; 6. Glutamine [administration & dosage]; 7. Head and Neck Neoplasms [complications, *surgery]; 8. Length of Stay; 9. Malnutrition [etiology, *therapy]; 10. Postoperative Complications [epidemiology, *prevention & control]; 11. Randomized Controlled Trials as Topic; 12. Surgical Wound Infection [epidemiology];
MESH terms:
Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations
1. *Genes, BRCA1; 2. *Genes, BRCA2; 3. Breast Neoplasms [mortality, *prevention & control]; 4. Heterozygote; 5. Mastectomy [*methods]; 6. Mutation [*genetics]; 7. Ovarian Neoplasms [mortality, *prevention & control]; 8. Quality of Life; 9. Salpingo‐oophorectomy [adverse effects, mortality, *statistics & numerical data];
MESH terms:
Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis
1. Brain Neoplasms [mortality, *radiotherapy, *secondary, *surgery]; 2. Combined Modality Therapy [methods, mortality]; 3. Cranial Irradiation [methods, mortality]; 4. Progression‐Free Survival; 5. Radiosurgery [adverse effects, *methods, mortality]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Virtual reality simulation training for health professions trainees in gastrointestinal endoscopy
1. *Clinical Competence; 2. *Virtual Reality; 3. Endoscopy, Gastrointestinal [*education]; 4. Health Personnel [*education]; 5. Randomized Controlled Trials as Topic; 6. Simulation Training [*methods];
MESH terms:
Home parenteral nutrition for people with inoperable malignant bowel obstruction
1. *Parenteral Nutrition, Home [adverse effects, mortality]; 2. Abdominal Neoplasms [complications]; 3. Intestinal Obstruction [etiology, mortality, *therapy]; 4. Observational Studies as Topic; 5. Quality of Life;
MESH terms:
Communication skills training for healthcare professionals working with people who have cancer
1. *Communication; 2. Anxiety [prevention & control]; 3. Caregivers [*education, psychology]; 4. Empathy; 5. Health Personnel [*education, psychology]; 6. Medical Oncology [*education]; 7. Neoplasms [psychology, *therapy]; 8. Oncology Nursing [education]; 9. Professional‐Patient Relations; 10. Randomized Controlled Trials as Topic; 11. Stress, Psychological [*prevention & control];
MESH terms:
Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review
1. Antibodies, Monoclonal, Humanized [adverse effects, *therapeutic use]; 2. Antineoplastic Agents, Immunological [adverse effects, *therapeutic use]; 3. Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; 4. Carcinoma [*drug therapy, pathology]; 5. Disease Progression; 6. Docetaxel; 7. Paclitaxel [administration & dosage]; 8. Quality of Life; 9. Taxoids [administration & dosage]; 10. Urinary Bladder Neoplasms [*drug therapy, pathology]; 11. Vinblastine [administration & dosage, analogs & derivatives];
MESH terms:
Anticoagulation for perioperative thromboprophylaxis in people with cancer
1. Anticoagulants [*administration & dosage, adverse effects]; 2. Blood Loss, Surgical [statistics & numerical data]; 3. Blood Transfusion [statistics & numerical data]; 4. Hemorrhage [chemically induced]; 5. Heparin [*administration & dosage, adverse effects]; 6. Heparin, Low-Molecular-Weight [*administration & dosage, adverse effects]; 7. Neoplasms [mortality, *surgery]; 8. Postoperative Complications [mortality, *prevention & control]; 9. Pulmonary Embolism [prevention & control]; 10. Randomized Controlled Trials as Topic; 11. Thrombocytopenia [prevention & control]; 12. Thrombosis [mortality, *prevention & control]; 13. Venous Thrombosis [prevention & control];
MESH terms:
Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery
1. Adrenal Cortex Hormones [*therapeutic use]; 2. Antipyrine [*analogs & derivatives, therapeutic use]; 3. Bevacizumab [adverse effects, *therapeutic use]; 4. Brain [diagnostic imaging, *radiation effects]; 5. Brain Edema [diagnostic imaging, drug therapy, etiology]; 6. Drug Therapy, Combination; 7. Edaravone; 8. Gadolinium; 9. Non‐Randomized Controlled Trials as Topic; 10. Radiation Injuries [diagnostic imaging, etiology, *therapy]; 11. Radiosurgery [adverse effects]; 12. Radiotherapy [adverse effects]; 13. Randomized Controlled Trials as Topic;
MESH terms:
Anticoagulation for people with cancer and central venous catheters
1. Anticoagulants [adverse effects, *therapeutic use]; 2. Catheter-Related Infections [epidemiology]; 3. Catheterization, Central Venous [*adverse effects]; 4. Heparin [adverse effects, therapeutic use]; 5. Heparin, Low-Molecular-Weight [adverse effects, therapeutic use]; 6. Neoplasms [mortality, *therapy]; 7. Randomized Controlled Trials as Topic; 8. Secondary Prevention [methods]; 9. Thrombocytopenia [chemically induced]; 10. Venous Thrombosis [etiology, mortality, *prevention & control]; 11. Vitamin K [antagonists & inhibitors];
MESH terms:
Primary cryotherapy for localised or locally advanced prostate cancer
1. *Cryotherapy [adverse effects, methods]; 2. Cause of Death; 3. Prostatic Neoplasms [mortality, pathology, radiotherapy, *therapy]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Stent placement versus surgical palliation for adults with malignant gastric outlet obstruction
1. *Duodenum; 2. *Stents [statistics & numerical data]; 3. Eating; 4. Gastric Outlet Obstruction [etiology, mortality, *surgery]; 5. Gastrointestinal Neoplasms [*complications]; 6. Length of Stay; 7. Palliative Care [*methods]; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Time Factors;
MESH terms:
Hormone replacement therapy for women previously treated for endometrial cancer
1. Breast Neoplasms [epidemiology]; 2. Early Termination of Clinical Trials; 3. Endometrial Neoplasms [*chemically induced, epidemiology, surgery]; 4. Estrogen Replacement Therapy [*adverse effects]; 5. Neoplasm Recurrence, Local [*chemically induced, epidemiology]; 6. Neoplasms, Second Primary [epidemiology]; 7. Quality of Life;
MESH terms:
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
1. Human papillomavirus 16; 2. Human papillomavirus 18; 3. Papillomavirus Infections [complications, mortality, *prevention & control]; 4. Papillomavirus Vaccines [*administration & dosage, adverse effects]; 5. Precancerous Conditions [mortality, *prevention & control, virology]; 6. Pregnancy Outcome; 7. Randomized Controlled Trials as Topic; 8. Uterine Cervical Dysplasia [mortality, *prevention & control, virology]; 9. Uterine Cervical Neoplasms [mortality, *prevention & control, virology]; 10. Vaccination;
MESH terms:
Hyperbaric oxygenation for tumour sensitisation to radiotherapy
1. Bronchial Neoplasms [mortality, radiotherapy]; 2. Combined Modality Therapy [methods]; 3. Esophageal Neoplasms [mortality, radiotherapy]; 4. Head and Neck Neoplasms [mortality, radiotherapy]; 5. Hyperbaric Oxygenation [adverse effects, *methods]; 6. Neoplasm Recurrence, Local [epidemiology]; 7. Neoplasms [mortality, *radiotherapy]; 8. *Radiation Tolerance; 9. Randomized Controlled Trials as Topic; 10. Rectal Neoplasms [mortality, radiotherapy]; 11. Time Factors; 12. Urinary Bladder Neoplasms [mortality, radiotherapy]; 13. Uterine Cervical Neoplasms [mortality, radiotherapy];
MESH terms:
Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas
1. Ampulla of Vater; 2. Antimetabolites, Antineoplastic [adverse effects, *therapeutic use]; 3. Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; 4. Biliary Tract Neoplasms [*drug therapy, mortality, pathology]; 5. Capecitabine [administration & dosage, adverse effects]; 6. Cholangiocarcinoma [*drug therapy, mortality, pathology]; 7. Cisplatin [administration & dosage, adverse effects]; 8. Deoxycytidine [adverse effects, *analogs & derivatives, therapeutic use]; 9. Drug Combinations; 10. Gallbladder Neoplasms [drug therapy, mortality, pathology]; 11. Mitomycin [administration & dosage, adverse effects]; 12. Organoplatinum Compounds [administration & dosage, adverse effects]; 13. Oxaliplatin; 14. Oxonic Acid [administration & dosage, adverse effects]; 15. Piperidines [administration & dosage, adverse effects]; 16. Quinazolines [administration & dosage, adverse effects]; 17. Randomized Controlled Trials as Topic; 18. Tegafur [administration & dosage, adverse effects];
MESH terms:
Breast surgery for metastatic breast cancer
1. Breast Neoplasms [mortality, *pathology, *surgery, therapy]; 2. Combined Modality Therapy [methods]; 3. Mastectomy; 4. Neoplasm Metastasis; 5. Prognosis; 6. Randomized Controlled Trials as Topic;
MESH terms:
Oral water soluble contrast for malignant bowel obstruction
1. Abdominal Neoplasms [*complications]; 2. Administration, Oral; 3. *Conservative Treatment; 4. Contrast Media [*administration & dosage, adverse effects]; 5. Diatrizoate Meglumine [*administration & dosage, adverse effects]; 6. Feasibility Studies; 7. Intestinal Obstruction [*diagnostic imaging, etiology, *therapy]; 8. Length of Stay; 9. Pilot Projects;
MESH terms:
Ghrelin for the management of cachexia associated with cancer
1. Body Composition [drug effects]; 2. Cachexia [etiology]; 3. *Eating; 4. Ghrelin [*administration & dosage, adverse effects]; 5. Neoplasms [*complications];
MESH terms:
Non‐steroidal anti‐inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia
1. Administration, Oral; 2. Anti-Inflammatory Agents, Non-Steroidal [administration & dosage, *therapeutic use]; 3. Celecoxib [therapeutic use]; 4. Cyclooxygenase 2 Inhibitors [administration & dosage, *therapeutic use]; 5. Disease Progression; 6. Induction Chemotherapy [*methods]; 7. Lactones [administration & dosage, therapeutic use]; 8. Placebos [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. Sulfonamides [administration & dosage, therapeutic use]; 11. Sulfones [administration & dosage, therapeutic use]; 12. Uterine Cervical Dysplasia [*drug therapy, pathology]; 13. Uterine Cervical Neoplasms [*drug therapy, pathology];
MESH terms:
Influenza vaccines in immunosuppressed adults with cancer
1. Adjuvants, Immunologic [administration & dosage]; 2. Bone Marrow Transplantation [mortality]; 3. Case‐Control Studies; 4. Cause of Death; 5. Cohort Studies; 6. Hematologic Neoplasms [immunology, mortality]; 7. Immunocompromised Host [*immunology]; 8. Influenza Vaccines [*administration & dosage, immunology]; 9. Influenza, Human [epidemiology, immunology, *prevention & control]; 10. Neoplasms [*immunology, mortality]; 11. Observational Studies as Topic; 12. Randomized Controlled Trials as Topic;
MESH terms:
Physical activity for women with breast cancer after adjuvant therapy
1. Anxiety [therapy]; 2. Breast Neoplasms [psychology, *therapy]; 3. Chemotherapy, Adjuvant; 4. Depression [therapy]; 5. *Exercise; 6. Fatigue [etiology]; 7. Physical Fitness; 8. Prognosis; 9. Quality of Life; 10. Radiotherapy, Adjuvant; 11. *Resistance Training;
MESH terms:
Selenium for preventing cancer
1. Case‐Control Studies; 2. Neoplasms [*prevention & control]; 3. Observational Studies as Topic; 4. Odds Ratio; 5. Randomized Controlled Trials as Topic; 6. Selenium [*administration & dosage, adverse effects]; 7. Sex Factors; 8. Trace Elements [*administration & dosage, adverse effects];
MESH terms:
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases
1. Brain Neoplasms [mortality, *radiotherapy, secondary, *surgery]; 2. Combined Modality Therapy; 3. Cranial Irradiation [methods, mortality]; 4. Dose Fractionation, Radiation; 5. Radiation-Sensitizing Agents [therapeutic use]; 6. Radiosurgery [adverse effects, methods]; 7. Randomized Controlled Trials as Topic; 8. Survival Analysis;
MESH terms:
Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers
1. Diarrhea [etiology, prevention & control]; 2. Gastrointestinal Agents [therapeutic use]; 3. Gastrointestinal Tract [drug effects, *radiation effects]; 4. Pelvic Neoplasms [*radiotherapy]; 5. Placebo Effect; 6. Radiation Injuries [*prevention & control]; 7. Radiotherapy, Conformal [*adverse effects]; 8. Radiotherapy, Intensity-Modulated [adverse effects]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Gefitinib for advanced non‐small cell lung cancer
1. Antineoplastic Agents [adverse effects, *therapeutic use]; 2. Carcinoma, Non‐Small‐Cell Lung [*drug therapy, ethnology, genetics]; 3. Disease‐Free Survival; 4. Gefitinib; 5. Genes, erbB‐1; 6. Lung Neoplasms [*drug therapy, ethnology, genetics]; 7. Mutation; 8. Quality of Life; 9. Quinazolines [adverse effects, *therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Treatment Failure;
MESH terms:
Bisphosphonates for advanced prostate cancer
1. *Prostatic Neoplasms; 2. Bisphosphonate‐Associated Osteonecrosis of the Jaw [epidemiology]; 3. Bone Density Conservation Agents [adverse effects, *therapeutic use]; 4. Bone Neoplasms [*drug therapy, mortality, *secondary]; 5. Diphosphonates [adverse effects, *therapeutic use]; 6. Kidney [drug effects]; 7. Nausea [chemically induced]; 8. Pain [*drug therapy, etiology]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Tumour bed boost radiotherapy for women after breast‐conserving surgery
1. *Postoperative Care; 2. *Re‐Irradiation [adverse effects]; 3. Breast Neoplasms [mortality, *radiotherapy, *surgery]; 4. Disease‐Free Survival; 5. Mastectomy, Segmental; 6. Neoplasm Recurrence, Local [mortality, prevention & control, radiotherapy]; 7. Neoplasm, Residual; 8. Randomized Controlled Trials as Topic;
MESH terms:
Closure methods for laparotomy incisions for preventing incisional hernias and other wound complications
1. *Abdominal Wound Closure Techniques; 2. *Laparotomy; 3. *Suture Techniques; 4. *Sutures; 5. Fistula [epidemiology]; 6. Incisional Hernia [epidemiology, *prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Surgical Wound Dehiscence [epidemiology]; 9. Surgical Wound Infection [epidemiology];
MESH terms:
Bisphosphonates and other bone agents for breast cancer
1. Administration, Oral; 2. Bone Density Conservation Agents [*therapeutic use]; 3. Bone Neoplasms [mortality, *prevention & control, *secondary]; 4. Breast Neoplasms [mortality, *pathology]; 5. Clodronic Acid [therapeutic use]; 6. Denosumab [therapeutic use]; 7. Diphosphonates [*therapeutic use]; 8. Imidazoles [therapeutic use]; 9. Injections, Intravenous; 10. Randomized Controlled Trials as Topic; 11. Zoledronic Acid;
MESH terms:
Lymphadenectomy for the management of endometrial cancer
1. Disease‐Free Survival; 2. Endometrial Neoplasms [*surgery]; 3. Lymph Node Excision [*adverse effects, mortality]; 4. Lymphatic Metastasis; 5. Lymphedema [etiology]; 6. Lymphocele [etiology]; 7. Postoperative Complications [etiology]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic;
MESH terms:
Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases
1. Brain Neoplasms [mortality, *radiotherapy, *secondary]; 2. Combined Modality Therapy [methods, mortality]; 3. Cranial Irradiation [*methods, mortality]; 4. Karnofsky Performance Status; 5. Radiosurgery [*methods, mortality]; 6. Randomized Controlled Trials as Topic; 7. Steroids [therapeutic use];
MESH terms:
Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic fistula following pancreaticoduodenectomy
1. *Pancreaticojejunostomy [adverse effects]; 2. Gastrostomy [*adverse effects]; 3. Length of Stay; 4. Pancreatectomy [*adverse effects]; 5. Pancreatic Fistula [*prevention & control]; 6. Pancreaticoduodenectomy [*adverse effects]; 7. Postoperative Complications [*prevention & control]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Intravesical electromotive drug administration for non‐muscle invasive bladder cancer
1. Administration, Intravesical; 2. Antibiotics, Antineoplastic [*administration & dosage]; 3. BCG Vaccine [administration & dosage]; 4. Carcinoma in Situ [*drug therapy, mortality, pathology]; 5. Carcinoma, Transitional Cell [*drug therapy, mortality, pathology]; 6. Disease Progression; 7. Electrochemotherapy [adverse effects, *methods]; 8. Mitomycin [*administration & dosage]; 9. Neoplasm Recurrence, Local; 10. Randomized Controlled Trials as Topic; 11. Time Factors; 12. Urinary Bladder Neoplasms [*drug therapy, mortality, pathology];
MESH terms:
Laparoscopic and robotic‐assisted versus open radical prostatectomy for the treatment of localised prostate cancer
1. Laparoscopy [adverse effects, *methods]; 2. Organ Size; 3. Prostate [pathology]; 4. Prostate‐Specific Antigen [blood]; 5. Prostatectomy [adverse effects, *methods]; 6. Prostatic Neoplasms [blood, mortality, pathology, *surgery]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Robotic Surgical Procedures [adverse effects, *methods]; 10. Sexual Behavior; 11. Urination;
MESH terms:
Parenteral anticoagulation in ambulatory patients with cancer
1. Anticoagulants [*administration & dosage, adverse effects]; 2. Cause of Death; 3. Hemorrhage [chemically induced, epidemiology]; 4. Heparin [*administration & dosage, adverse effects]; 5. Heparin, Low-Molecular-Weight [administration & dosage]; 6. Neoplasms [*mortality]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Survival Analysis; 10. Time Factors; 11. Venous Thromboembolism [epidemiology, *prevention & control]; 12. Warfarin [administration & dosage];
MESH terms:
Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia
1. Antineoplastic Agents [*therapeutic use]; 2. Dactinomycin [*therapeutic use]; 3. Gestational Trophoblastic Disease [epidemiology, *prevention & control]; 4. Hydatidiform Mole [*drug therapy]; 5. Incidence; 6. Methotrexate [*therapeutic use]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation
1. *Consolidation Chemotherapy; 2. Adrenal Gland Neoplasms [mortality, *therapy]; 3. Antineoplastic Agents [administration & dosage, *therapeutic use]; 4. Bone Marrow Transplantation; 5. Disease‐Free Survival; 6. Hematopoietic Stem Cell Transplantation [*methods]; 7. Neuroblastoma [mortality, *therapy]; 8. Randomized Controlled Trials as Topic; 9. Selection Bias; 10. Tretinoin [administration & dosage, *therapeutic use];
MESH terms:
Home‐based multidimensional survivorship programmes for breast cancer survivors
1. Anxiety [rehabilitation]; 2. Breast Neoplasms [*rehabilitation, therapy]; 3. Depression [rehabilitation]; 4. *Exercise; 5. Fatigue [rehabilitation]; 6. Home Care Services; 7. Non-Randomized Controlled Trials as Topic; 8. Patient Education as Topic [methods, *organization & administration]; 9. Prognosis; 10. *Program Evaluation; 11. *Quality of Life; 12. Randomized Controlled Trials as Topic; 13. Sleep Initiation and Maintenance Disorders [rehabilitation]; 14. Survival Rate; 15. *Survivors;
MESH terms:
Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer
1. *Chemoradiotherapy [adverse effects, mortality]; 2. *Esophagectomy [mortality]; 3. Carcinoma [mortality, pathology, surgery, therapy]; 4. Carcinoma, Squamous Cell [mortality, pathology, surgery, *therapy]; 5. Cisplatin; 6. Combined Modality Therapy [adverse effects, methods, mortality]; 7. Deglutition Disorders [therapy]; 8. Esophageal Neoplasms [mortality, pathology, surgery, *therapy]; 9. Fluorouracil [administration & dosage]; 10. Neoplasm Recurrence, Local; 11. Quality of Life; 12. Randomized Controlled Trials as Topic;
MESH terms:
Procarbazine, lomustine and vincristine for recurrent high‐grade glioma
1. Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; 2. Brain Neoplasms [*drug therapy, mortality]; 3. Cytarabine [administration & dosage]; 4. Dacarbazine [administration & dosage, adverse effects, analogs & derivatives]; 5. Disease Progression; 6. Disease‐Free Survival; 7. Drug Administration Schedule; 8. Glioma [*drug therapy, mortality]; 9. Hydroxyurea [administration & dosage]; 10. Lomustine [*administration & dosage, adverse effects]; 11. Methylprednisolone [administration & dosage]; 12. Neoplasm Recurrence, Local [*drug therapy, mortality]; 13. Procarbazine [*administration & dosage, adverse effects]; 14. Randomized Controlled Trials as Topic; 15. Temozolomide; 16. Vincristine [administration & dosage, adverse effects];
MESH terms:
Non‐steroidal anti‐inflammatory drugs (NSAIDs) for cancer‐related pain in children and adolescents
1. Anti‐Inflammatory Agents, Non‐Steroidal [*therapeutic use]; 2. Cancer Pain [*drug therapy];
MESH terms:
Opioids for cancer‐related pain in children and adolescents
1. Analgesics, Opioid [*therapeutic use]; 2. Cancer Pain [*drug therapy];
MESH terms:
Psychosocial interventions for fatigue during cancer treatment with palliative intent
1. Activities of Daily Living; 2. Cognition; 3. Fatigue [etiology, physiopathology, psychology, *therapy]; 4. Neoplasms [*complications, physiopathology, psychology, therapy]; 5. Palliative Care [*methods]; 6. Psychotherapy [*methods]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Social Skills;
MESH terms:
Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults
1. Administration, Oral; 2. Analgesics, Opioid [administration & dosage]; 3. Anti‐Inflammatory Agents, Non‐Steroidal [*administration & dosage, adverse effects]; 4. Cancer Pain [*drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Withholding Treatment [statistics & numerical data];
MESH terms:
Oral paracetamol (acetaminophen) for cancer pain
1. Acetaminophen [*administration & dosage]; 2. Administration, Oral; 3. Analgesics, Non‐Narcotic [*administration & dosage]; 4. Analgesics, Opioid [administration & dosage]; 5. Anti‐Inflammatory Agents, Non‐Steroidal [administration & dosage]; 6. Antidepressive Agents, Tricyclic [administration & dosage]; 7. Antipsychotic Agents [administration & dosage]; 8. Cancer Pain [*drug therapy]; 9. Drug Therapy, Combination; 10. Patient Preference; 11. Quality of Life; 12. Randomized Controlled Trials as Topic;
MESH terms:
Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery)
1. Adrenal Cortex Hormones [adverse effects, *therapeutic use]; 2. Chlorpromazine [adverse effects, therapeutic use]; 3. Dexamethasone [adverse effects, therapeutic use]; 4. Indoles [adverse effects, therapeutic use]; 5. Metoclopramide [adverse effects, therapeutic use]; 6. Nausea [*drug therapy, etiology]; 7. Neoplasms [*complications]; 8. Time Factors; 9. Tropisetron; 10. Vomiting [*drug therapy, etiology];
MESH terms:
Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in women with gynaecological malignancies
1. Drainage [*methods]; 2. Genital Neoplasms, Female [*surgery]; 3. Lymph Node Excision [*adverse effects]; 4. Lymphocele [etiology, *prevention & control]; 5. Pelvis; 6. Randomized Controlled Trials as Topic; 7. Retroperitoneal Space; 8. Suction [methods];